Richard Marshall Accepts New Role at TriSalus Life Sciences

TriSalus Life Sciences Inc. has named Richard Marshall, M.D., as chief medical officer, effective June 29. He is currently the company’s medical director, a position he has held since January 2025.

In his new role, Dr. Marshall will lead TriSalus Life Sciences’ medical strategy and provide clinical leadership across development, evidence generation, and broader strategic initiatives.

“Dr. Marshall brings a rare combination of frontline clinical insight and deep interventional oncology expertise that is uniquely aligned with our mission. Since joining TriSalus as medical director, he has been an invaluable clinical voice in driving the expansion of our TriNav product suite and proprietary Pressure-Enabled Drug Delivery (PEDD) platform across a broad range of indications beyond the liver,” TriSalus Life Sciences President/CEO Mary Szela said. “As we continue to see strong physician engagement, utilization and interest in the PEDD platform, Dr. Marshall’s appointment as chief medical officer positions us to accelerate the advancement of our clinical and economic advantages data and deliver meaningful impact for patients.”

Dr. Marshall is an interventional radiologist with extensive experience spanning interventional oncology, hepatobiliary interventions, and trauma care. After graduating from Tulane University School of Medicine, he completed his diagnostic radiology residency at Ochsner Clinic Foundation, where he served as chief resident, followed by fellowship training in interventional radiology and interventional oncology at Weill Cornell University and Memorial Sloan Kettering Cancer Center in New York. He joined the faculty at Louisiana State University Health Sciences Center and then Tulane University, both in New Orleans.

During his time at LSU Health Sciences Center, Dr. Marshall developed Louisiana’s first Interventional Radiology Residency and led a high-volume clinical practice focused on interventional oncology, hepatobiliary interventions, and trauma care. Since 2021, he has also served at Tulane University School of Medicine, where he has remained active in medical student and resident education. His clinical experience has included care for patients undergoing organ transplantation, pediatric interventions, embolization for thyroid disease and uterine fibroids, musculoskeletal pain palliation, venous interventions, and palliative care.

“I am honored to step into the chief medical officer role at TriSalus at this important time,” Dr. Marshall stated. “TriSalus is working to address significant challenges in the treatment of liver and pancreatic tumors to provide meaningful benefits to patients. I look forward to helping advance the company’s medical and clinical efforts as we continue to build on the potential of the PEDD approach and support better and safer patient outcomes.”

TriSalus Life Sciences is an oncology-focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies and with its investigational immunotherapeutic, nelitolimod. The company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s three U.S. Food and Drug Administration-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors, and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a delivery approach that addresses the anatomic limitations of arterial pancreas infusion. The PEDD approach modulates pressure and flow to deliver more therapy to the tumor and reduces undesired delivery to normal tissue, bringing the potential to improve patient outcomes. TriSalus Life Sciences is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.